Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclacel Pharmaceuticals, Inc.
With
M.D. Anderson Cancer Center
This is a First in Human, open-label, single arm, dose escalation study in patients with advanced leukemias or myelodysplastic syndromes. Patients will receive CYC140 as a 1 hr infusion once a week for 2 weeks followed by 1 week of rest on an outpatient basis. One treatment cycle is 3 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of relapsed or refractory advanced leukemias or MDS
ECOG 0-2
Adequate renal function
Adequate liver function
≥ 2 weeks from prior chemotherapy, radiation therapy or major surgery
≥ 4 weeks from other investigational anticancer therapy
Agree to practice effective contraception
You may not be if
Known CNS involvement by leukemia
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Uncontrolled intercurrent illness
Pregnant or lactating
Known to be HIV-positive
Known active hepatitis B and/ or hepatitis C infection
Clareo Health | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
